Molecular characterization of Glanzmann's thrombasthenia in Iran: Identification of three novel mutations

Kazemi, A. and Abolghasemi, H. and Kazemzadeh, S. and Vahidi, R. and Faranoush, M. and Farsinejad, A. and Ala, F. (2017) Molecular characterization of Glanzmann's thrombasthenia in Iran: Identification of three novel mutations. Blood Coagulation and Fibrinolysis, 28 (8). pp. 681-686.

Full text not available from this repository.
Official URL:


Quantitative and/or qualitative defects of the platelet membrane glycoprotein IIb/IIIa complex lead to the clinical entity of Glanzmann's thrombasthenia. A large variety of mutations and polymorphisms are responsible for the aberrant expression and defective activity of this heterodimeric complex. The current study aimed to determine the pattern of mutations among Iranian population with Glanzmann's thrombasthenia. A total of 20 patients with Glanzmann's thrombasthenia have been evaluated. All exons and splice sites of ITGA2B and ITGB3 genes were amplified using touchdown PCR. Mutation screening was analyzed using conformation sensitive gel electrophoresis heteroduplex PCR, and DNA sequencing. In addition to finding one previously identified mutation and polymorphism, the experimenters explored 3 and 2 novel mutations and polymorphisms, respectively. One substitution mutation, two deletions of a single nucleotide, one insertion of a single nucleotide, two synonymous polymorphisms, and one missense polymorphism were found using Sanger sequencing method. All detected mutations were homozygous which will most likely contribute to the pathogenesis of Glanzmann's thrombasthenia. Furthermore, it suggested ITGB3 as the mainly affected gene impaired in the patients with Glanzmann's thrombasthenia. As expected, the molecular results were consistent with the phenotypic findings so that GPIIb/IIIa complex was disrupted due to mutations in all type-I Glanzmann's thrombasthenia patients. It is concluded that intronic alterations or epigenetic regulations could be responsible for aberrant expression and/or defective activity of GPIIb/IIIa complex among other patients. © 2017 Wolters Kluwer Health, Inc. All rights reserved.

Item Type: Article
Additional Information: cited By 0
Uncontrolled Keywords: alpha2 integrin; beta3 integrin; glycoprotein Ib; glycoprotein Ib alpha; glycoprotein IIb; glycoprotein IIIa; integrin alpha 2b; messenger RNA; unclassified drug; alpha2 integrin; beta3 integrin; fibrinogen receptor; ITGA2B protein, human; ITGB3 protein, human, adult; Article; child; clinical article; DNA sequence; exon; female; gel electrophoresis; gene amplification; gene deletion; gene insertion; Glanzmann disease; heteroduplex analysis; homozygote; human; male; missense mutation; molecular pathology; mutational analysis; nucleotide sequence; polymerase chain reaction; priority journal; RNA splice site; Sanger sequencing; school child; single nucleotide polymorphism; young adult; epidemiology; genetics; Glanzmann disease; Iran; molecular epidemiology; mutation, Homozygote; Humans; Integrin alpha2; Integrin beta3; Iran; Molecular Epidemiology; Mutation; Platelet Glycoprotein GPIIb-IIIa Complex; Sequence Analysis, DNA; Thrombasthenia
Subjects: WH Hemic and Lymphatic Systems
Depositing User: eprints admin
Date Deposited: 30 Dec 2018 07:22
Last Modified: 30 Dec 2018 07:22

Actions (login required)

View Item View Item